CalciMedica (CALC)

• Market cap: $9.09M
• 1 day: -21.68%
• 5 days: -32.45%
• 1 month: 6.77%
• 3 months: -90.73%
• 6 months: -82.12%
• Year to date: -91.43%
• 1 year: -72.5%
• 5 years: -99.45%
• 10 years: -99.75%
• Sector: Healthcare
• Industry: Biotechnology

About: CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Employees: 16